Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 6NIH 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2NET 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Differentiated Thyroid Cancer 1

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Iodine-131 × Endocrine × Clear all
NCT04964284 2023-10-23

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Unknown
328 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡